METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
Targeted drugs are recommended for treatment of metastatic colorectal cancer. Second and further lines therapy options include anti-EGFR therapy, eligible for patients with wild-type KRAS (cetuximab and panitumumab), and relatively new drug — regorafenib, which could be used for all patients.The aim...
| 出版年: | Фармакоэкономика |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | 論文 |
| 言語: | ロシア語 |
| 出版事項: |
IRBIS LLC
2016-09-01
|
| 主題: | |
| オンライン･アクセス: | https://www.pharmacoeconomics.ru/jour/article/view/146 |